Advance reports: ENGAGE AF TIMI-48 study: new results for edoxaban

ENGAGE AF TIMI-48 study: new results for edoxaban Results from the phase 3 ENGAGE AF-TIMI 48 study were announced at the American Heart Association (AHA) Scientific Sessions in Dallas. It found that the investigational, oral, once-daily direct factor Xa-inhibitor edoxaban, evaluated in two treatment arms (60mg and 30mg), achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism (SEE) in patients with non-valvular atrial fibrillation (NVAF). ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation) was a three-arm, randomised, double-blind, double-dummy, global phase 3 clinical trial comparing once-daily edoxaban